Please assess the completion status of the following clinical trial:

Trial Title: Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed as schizophrenia by DSM-IV-TR criteria both in inpatients~* Patients who are symptomatically stable, as judged by the treating psychiatrist, and receive a stable dose of risperidone for a minimum of 2 weeks before enrollment.~* Patients with ability to complete various questionnaires.~* Patients and/or their legal guardians/representatives who sufficiently understand the objective of the study and sign informed consent form~Exclusion Criteria:~* Active psychotic symptoms, including severe behavioral disturbance~* Relevant history of or current presence of any significant or unstable medical disease~* A woman who is pregnant, breast-feeding or planning to become pregnant during the study period~* Patients with the history of serious allergy or multiple adverse drug reactions~* Patients with the history of taking paliperidone ER within 60 days~* Patients with history of taking clozapine within 60 days~* Patients who require the treatment of other medications influencing CNS, except permitted concomitant drugs in advance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- 1. Paliperidone ER (Type: EXPERIMENTAL): New antipsychotics
- 2 Risperidone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).